

MyMelanoma Charitable Incorporated Organisation (CIO)

First Report of the Trustees for the period 16 November 2023 to 31 March 2025

This is the first report of the Trustees since the establishment of MyMelanoma CIO on 16th November 2023. It accompanies the first set of Accounts.

About MyMelanoma

Despite advances in melanoma care, doctors worldwide diagnose hundreds of new cases of melanoma daily and this is increasing with the 15-34-year-old age group more vulnerable. Our aim is to develop the first digital platform, creating real data derived from a patient centered collaboration with researchers, medics and scientists, to enable better care and cure in the next 10 years. With the mantra "Involve, Research, Care, Cure" at its core, MyMelanoma is a one-of-a-kind and collaborative research project working with melanoma sufferers to facilitate the most ambitious melanoma patient study ever conducted.

Our Goals

The relief of sickness and the preservation and protection of good health of persons suffering from melanoma by:

- a. Developing a melanoma patient database which can be accessed worldwide by experts in the field;
- b. Promoting research into the causes, treatments and cures of melanoma; and
- c. Advancing education in melanoma and its prevention and care amongst the public, patients and healthcare professionals.

Building the MyMelanoma Charity

In 2021 a working group of interested parties held initial workshops and meetings to shape MyMelanoma. Although its purpose and model was proposed before 2021. Further shaping work led to a Board with Terms of Reference being formed and an Operational Team to further shape how MyMelanoma would operate and to create a plan to establish MyMelanoma as a Charity for research purposes. The MyMelanoma Board approved a Constitution in December 2022. Subsequently, slightly amended in October 2023 following feedback from the Charity Commission.

MyMelanoma was registered as a Charity on 16th November 2023. MyMelanoma was registered with HMRC as a Charitable Incorporated Organisation.

In June 2023 a bank account was opened with Lloyds Bank.

At present the MyMelanoma charity depends on volunteers and has no employees or paid contractors.

MyMelanoma website and Patient Portal

MyMelanoma Charitable Incorporated Organisation (CIO)

MyMelanoma is taking lessons from eCommerce and Business-to-Customer models. Gathering Patient data using traditional approaches is expensive requiring considerable human resources. MyMelanoma has built a website which provides access to a highly secure Patient Portal. This ground-breaking data capture model, made fully operational in this reporting period, enables melanoma patients and their families to register their wish to take part in the MyMelanoma Study. They are able to respond to online questionnaires which builds into a database. This database is then available for research by accredited bodies.

An initial target of 20,000 registered and active patients was set for a first phase of patient recruitment. In January 2025 MyMelanoma's partner, Oxford Cancer (part of Oxford University) funded communication with 117,000 UK melanoma patients, during 2025, inviting them to take part in the study. By the end of February 2025, 5000 patients had registered with the Portal.

N.B. By the end of October 2025 more than 15,000 patients have registered.

Finance and Fund raising

MyMelanoma was in receipt of funding and donations prior to its formal charitable status. The charity Melanoma Focus provided funds to establish the initial website and test patient portal. Charity fun rides raised nearly £14,000 which was held on behalf of MyMelanoma by Leeds University, a collaborating partner. These funds were transferred to MyMelanoma once we had opened the bank account at Lloyds.

There have also been personal donations which are reflected in the Accounts.

For public fund raising a page has been established on the JustGiving website.

Operational costs were funded to March 2025 by our Oxford Cancer partner.

Income for the period: £15,879.55, mostly from donations

Costs for the period: £455.50, mostly maintaining the website URL registration.

Current and savings account balance: £16010.85.

Plan for the 2025-26 Year and further ahead

It is planned to link the JustGiving page to fund raising events and to publicise through social media.

Oxford Cancer continue to fund and run MyMelanoma Operations:

- Website and Patient Portal
- Patient study including writing to 117,000 melanoma patients
- Establishment of patient tissue/blood sample storage.

The MyMelanoma charity operations team are seeking fund raising partners and suitable sponsors. Our partners at Oxford Cancer are also making contacts with potential collaborators and partners. The intention is to raise sufficient recurring funds to take over funding all operations currently funded by Oxford Cancer. And raise additional funds to enable research.

MyMelanoma Charitable Incorporated Organisation (CIO)

Report approved the Trustees:

Mark Middleton

Sean Guinness

Adrian Pyne

MYMELANOMA

A CHARITABLE INCORPORATED ORGANISATION (CIO)
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2025

MYMELANOMA

LEGAL AND ADMINISTRATIVE INFORMATION

FOR THE YEAR ENDED 31 MARCH 2025

Trustees

Mark Ross Middleton
ADRIAN VINCENT ASHLEY PYNE
Sean Peter Guinness

Charity Number

1205749

Registered Office

HORNS HILL
NETHER COMPTON
SHERBORNE
DT9 4QA

MYMELANOMA

CONTENTS

FOR THE YEAR ENDED 31 MARCH 2025

Trustees' Report

Statement of Financial Activities

Balance Sheet

Notes to the Financial Statements

MYMELANOMA

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their annual report and financial statements for the year ended 31 March 2025.

Trustees' report and financial statements

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Trustees

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

ADRIAN VINCENT ASHLEY PYNE

Trustees' responsibilities statement

The trustees, who are also the directors of Charity For Mymelanoma for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report was approved by the trustees and signed on its behalf by:

ADRIAN VINCENT ASHLEY PYNE

Trustee

Date : **16 December 2025**

MYMELANOMA

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 MARCH 2025

Recommended categories by activity	Notes	Unrestricted funds £	Total Funds 2025 £
Income and endowments from:			
Donations and legacies	2	15,890.29	15,890.29
Total		15,890.29	15,890.29
Expenditure on:			
Raising funds	3	329.99	329.99
Other	4	59.50	59.50
Total		389.49	389.49
Net income		15,500.80	15,500.80
Net movement in funds		15,500.80	15,500.80
Reconciliation of funds:			
Total funds brought forward		-	-
Total funds carried forward		15,500.80	15,500.80

MYMELANOMA

BALANCE SHEET

FOR THE YEAR ENDED 31 MARCH 2025

Recommended categories by activity	Notes	Total Funds 2025 £
Current assets		
Cash at bank and in hand	5	15,464.80
Total current assets		15,464.80
Creditors: amounts falling due within one year	6	(36.00)
Net current assets/(liabilities)		15,500.80
Total net assets		15,500.80
Funds of the Charity		
Unrestricted funds	7	15,500.80
Restricted income funds	7	-
Endowment funds	7	-
Total funds		15,500.80

For the year ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.

The trustees acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 16 December 2025 and signed on its behalf by:

ADRIAN VINCENT ASHLEY PYNE
Trustee

Date : **16 December 2025**

MYMELANOMA

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

1. Accounting Policies

The principal accounting policies adopted by the Charity, which is a public benefit entity, in the preparation of the accounts are as follows.

1.1 Basis of preparation

These accounts have been prepared under the historical cost convention, as modified by the inclusion of charitable properties and fixed asset investments and investment properties at valuation.

These accounts have been prepared in accordance with "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

These accounts are presented in pounds sterling and rounded to the nearest pound.

1.2 Going concern

The Trustees have prepared financial projections, taking into consideration the current economic conditions and have, at the time of approving these accounts, a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the accounts.

2. Income from Donations and Legacies

Analysis	Unrestricted funds	Total funds 2025
	£	£
Donation and gifts	15,879.55	15,879.55
Other	10.74	10.74
Total	15,890.29	15,890.29

3. Expenditure on Raising Funds

Analysis	Unrestricted funds	Total funds 2025
	£	£
Advertising, marketing, direct mail and publicity	329.99	329.99
Total	329.99	329.99

4. Other Expenditure

Analysis	Unrestricted funds	Total funds 2025
	£	£
Bank charges	59.50	59.50
Total	59.50	59.50

5. Cash at bank and in hand

	Total funds 2025
	£
Cash at bank and in hand	15,464.80
Total	15,464.80

6. Creditors: Amounts falling due within one year

	Total funds 2025
	£
VAT control	(36.00)
Total	(36.00)

7. Charity funds

7.1 Details of material funds held and movements during the CURRENT reporting period

Fund names	Fund balances brought forward	Income	Expenditure	Transfers	Gains and losses	Fund balances carried forward
	£	£	£	£	£	£
Unrestricted funds						
	-	15,890.29	389.49	-	-	15,500.80